fda approved glp 1 agonists GLP-1 Agonists: A Comprehensive Overview Mapping the effectiveness and risks
Description
The role of evidence in the rise and fall of insulin coma therapy', History of Psychiatry , 33/1, 65-71
Based on the current evidence, GLP-1RAs should be considered alongside other guideline-directed medical therapies for HFpEF when indicated for T2D or obesity
First, the lower levels of active incretin compared to healthy subjects due to the increased degradation by dipeptidyl peptidase-4 and reduced incretin production in patients with NAFLD may explain the beneficial effect of GLP-1RA in NAFLD treatment [44]
Obesity induces metabolic disturbances in adipose tissue, influencing the release of hormones, adipokines, inflammatory cytokines, growth factors, enzymes, and free fatty acids [12]
Coskun T, Sloop KW, Loghin C, et al
2018 173:321337.e10
